This drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy for clinical use in treating neovascular age-related macular degeneration (nAMD). The US FDA has cleared an investigational new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback